Correction: The Parkinson's disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons

Jace Jones-Tabah^{1

2}, Kathy He¹, Nathan Karpilovsky¹, Konstantin Senkevich^{1

2}, Ghislaine Deyab¹, Isabella Pietrantonio¹, Thomas Goiran¹, Yuting Cousineau², Daria Nikanorova³, Taylor Goldsmith⁴, Esther Del Cid Pellitero¹, Carol X-Q Chen⁴, Wen Luo⁴, Zhipeng You⁴, Narges Abdian⁴, Jamil Ahmad^{1

2}, Jennifer A Ruskey^{1

2}, Farnaz Asayesh^{1

5}, Dan Spiegelman¹, Stanley Fahn⁶, Cheryl Waters⁶, Oury Monchi^{2

7

8}, Yves Dauvilliers⁹, Nicolas Dupré^{10

11}, Irina Miliukhina¹², Alla Timofeeva¹³, Anton Emelyanov¹³, Sofya Pchelina¹³, Lior Greenbaum¹⁴, Sharon Hassin-Baer^{14

15

16}, Roy N Alcalay^{6

17}, Austen Milnerwood², Thomas M Durcan⁴, Ziv Gan-Or^{1

5}, Edward A Fon^{18

19}

Affiliations

¹ Neurodegenerative Diseases Group, Department of Neurology and Neurosurgery, McGill Parkinson Program, Montreal Neurological Institute-Hospital, McGill University, Montreal, Québec, Canada.
² Department of Neurology and Neurosurgery, McGill University, Montréal, Canada.
³ Research Department, Bioinformatics Institute, Saint-Petersburg, Russia.
⁴ Early Drug Discovery Unit (EDDU), Montreal Neurological Institute-Hospital, McGill University, Montreal, Canada.
⁵ Department of Human Genetics, McGill University, Montréal, Canada.
⁶ Department of Neurology, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA.
⁷ Département de Radiologie, Radio-Oncologie Et Médecine Nucléaire, Université de Montréal, Montréal, QC, Canada.
⁸ Centre de Recherche de L'Institut Universitaire de Gériatrie de Montréal, Montréal, QC, Canada.
⁹ Sleep Unit, Department of Neurology, National Reference Center for Narcolepsy, Gui-de-Chauliac Hospital, CHU Montpellier, University of Montpellier, Montpellier, France.
¹⁰ Neuroscience Axis, CHU de Québec - Université Laval, Quebec City, G1V 4G2, Canada.
¹¹ Department of Medicine, Faculty of Medicine, Université Laval, Québec, QC, G1V 0A6, Canada.
¹² Institute of the Human Brain of RAS, St. Petersburg, Russia.
¹³ First Pavlov State Medical, University of St. Petersburg, Saint-Petersburg, Russia.
¹⁴ Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
¹⁵ The Joseph Sagol Neuroscience Center, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
¹⁶ Department of Neurology, The Movement Disorders Institute, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
¹⁷ Neurological Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
¹⁸ Neurodegenerative Diseases Group, Department of Neurology and Neurosurgery, McGill Parkinson Program, Montreal Neurological Institute-Hospital, McGill University, Montreal, Québec, Canada. ted.fon@mcgill.ca.
¹⁹ Department of Neurology and Neurosurgery, McGill University, Montréal, Canada. ted.fon@mcgill.ca.

PMID: 39696367
PMCID: PMC11657430
DOI: 10.1186/s13024-024-00791-z

Published Erratum

Correction: The Parkinson's disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons

Jace Jones-Tabah et al. Mol Neurodegener. 2024.

. 2024 Dec 18;19(1):94.

doi: 10.1186/s13024-024-00791-z.

Authors

Affiliations

¹ Neurodegenerative Diseases Group, Department of Neurology and Neurosurgery, McGill Parkinson Program, Montreal Neurological Institute-Hospital, McGill University, Montreal, Québec, Canada.
² Department of Neurology and Neurosurgery, McGill University, Montréal, Canada.
³ Research Department, Bioinformatics Institute, Saint-Petersburg, Russia.
⁴ Early Drug Discovery Unit (EDDU), Montreal Neurological Institute-Hospital, McGill University, Montreal, Canada.
⁵ Department of Human Genetics, McGill University, Montréal, Canada.
⁶ Department of Neurology, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA.
⁷ Département de Radiologie, Radio-Oncologie Et Médecine Nucléaire, Université de Montréal, Montréal, QC, Canada.
⁸ Centre de Recherche de L'Institut Universitaire de Gériatrie de Montréal, Montréal, QC, Canada.
⁹ Sleep Unit, Department of Neurology, National Reference Center for Narcolepsy, Gui-de-Chauliac Hospital, CHU Montpellier, University of Montpellier, Montpellier, France.
¹⁰ Neuroscience Axis, CHU de Québec - Université Laval, Quebec City, G1V 4G2, Canada.
¹¹ Department of Medicine, Faculty of Medicine, Université Laval, Québec, QC, G1V 0A6, Canada.
¹² Institute of the Human Brain of RAS, St. Petersburg, Russia.
¹³ First Pavlov State Medical, University of St. Petersburg, Saint-Petersburg, Russia.
¹⁴ Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
¹⁵ The Joseph Sagol Neuroscience Center, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
¹⁶ Department of Neurology, The Movement Disorders Institute, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
¹⁷ Neurological Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
¹⁸ Neurodegenerative Diseases Group, Department of Neurology and Neurosurgery, McGill Parkinson Program, Montreal Neurological Institute-Hospital, McGill University, Montreal, Québec, Canada. ted.fon@mcgill.ca.
¹⁹ Department of Neurology and Neurosurgery, McGill University, Montréal, Canada. ted.fon@mcgill.ca.

PMID: 39696367
PMCID: PMC11657430
DOI: 10.1186/s13024-024-00791-z

No abstract available

PubMed Disclaimer

Erratum for

The Parkinson's disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons.
Jones-Tabah J, He K, Karpilovsky N, Senkevich K, Deyab G, Pietrantonio I, Goiran T, Cousineau Y, Nikanorova D, Goldsmith T, Del Cid Pellitero E, Chen CX, Luo W, You Z, Abdian N, Ahmad J, Ruskey JA, Asayesh F, Spiegelman D, Fahn S, Waters C, Monchi O, Dauvilliers Y, Dupré N, Miliukhina I, Timofeeva A, Emelyanov A, Pchelina S, Greenbaum L, Hassin-Baer S, Alcalay RN, Milnerwood A, Durcan TM, Gan-Or Z, Fon EA. Jones-Tabah J, et al. Mol Neurodegener. 2024 Nov 25;19(1):88. doi: 10.1186/s13024-024-00779-9. Mol Neurodegener. 2024. PMID: 39587654 Free PMC article.

References

1. Jones-Tabah J, He K, Karpilovsky N, et al. The Parkinson’s disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons. Mol Neurodegeneration. 2024;19:88. 10.1186/s13024-024-00779-9. - PMC - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- BioMed Central
- PubMed Central

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Correction: The Parkinson's disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons

Affiliations

Correction: The Parkinson's disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons

Authors

Affiliations

Erratum for

References

Publication types

LinkOut - more resources

Full Text Sources